CDK4 and neoplasm: We have shown that the currently available targeted tumor genotyping panels can reliably detect these molecular amplifications in MDM2 and CDK4. This is useful as it provides a potential therapeutic target; MDM2 and CDK4 inhibitors are being tested in various clinical trials.